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Expression of Bcl-2 and androgen receptors in carcinoma of the prostate.
Paul Halliday, Ken Grigor*, Found K Habib
University Department of Surgery (WGH) and Pathology*, Western General 
Hospital, Edinburgh, Scotland, UK.
The bcl-2 proto-oncogene is said to contribute to malignant cell expansion 
primarily by prolonging cell survival rather than by increasing the rate of cellular 
proliferation, ir\ other words by dela) ing or blocking apoptosis. It has been 
studied in a number of malignanries including breast, thyroid, neuroblastoma 
and lung where loss of bcl-2 expression would appear to correlate with poor 
prognosis. In contrast, some studies in prostate cancer have suggested that high 
levels of expression are associated with disease progression following androgen 
ablation. We set out to examine bcl-2 and androgen receptor (AR) expression in 
prostate cancer with a view to relating expression to clinical outcome.
We studied 10 cases of benign prostate, 7 androgen - dependant cancers and 8 
cases of progressive cancer following androgen ablation. Using 
immunohistochemistry, paraffin tissue sections from transurethral prostatectomy 
specimens were stained for bcl-2 and AR using mouse monoclonal antibodies. 
Antibody specificty was confirmed by Western blotting. The benign cases all 
stained similarly for bci-2 with basal glandular cells and lymphocytes positive. 
For AR there was good nuclear staining in the glands with weak 
nuclear/cytoplasmic staining in the epithelium of the prostatic ducts and 
urethra. Smooth muscle from prostate stained better than smooth muscle from 
bladder neck.
In the cancers, only areas of malignant disease were studied. Of the 7 
androgen-dependant cancers, 2 showed moderate staining for bcl-2, 3 were 
wenkand 2 negative. In the 8 androgen-independant cases, 1 showed moderate 
staining, 1 was weak and 6 negative. In regard to AR, only 1 of the androgen- 
dependant group was negative, in contrast to half of the androgen-independant 
group. In general, the solid, poorly differentiated cancers were negative but AR 
expression did not correlate well with bcl-2 expression.
Our results suggest that in prostate cancer, as in other cancers, loss of bcl-2 
expression correlates with disease which is less responsive to treatment, We are 
currently examining larger numbers of both treated and untreated patients and 
are correlating our findings with the number of apoptotic cells in each case, 
(supported by Royal College of Surgeons of Edinburgh and by the Prostate 
Cancer Research Campaign).
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A RETROSPECTIVE STUDY O F H IG H  M OBILITY GROU 
PROTEIN I(Y) AS PROGRESSION M A R K E R  IN PROSTATl 
CANCER DETERM INED BY IN-SITU H Y BRID IZA TIO N
Yahya Tamimi, Henk G. van der Poel, Herbert F, M. Karthaus, Fran 
M. J. Debruyne and Jack A. Schalken. Urological Research laboratory 
Nijmegen the Netherlands.
In a previous study using RNA in-situ hybridization, we found « 
significant correlation between high mobility group protein I/Y, (HMG 
I(Y)) mRNA expression and tumor stage and grade in prostate cancci 
patients, suggesting that HMG-I(Y) might be a potential prognostk 
marker in prostate cancer. However, our clinical follow up was limitec 
because cryopreserved material was used. Assessing the potentia 
prognostic value of this molecule is of importance because the clinical 
course of prostate cancer patients remains unpredictable. Here we 
describe our results on paraffin embedded archival material from a 
group of 102 patients undergoing radical prostatectomy. These were 
evaluated for the presence of HMG-I(Y) using R N A  in situ hybridization 
and a follow up of 12-92 months (average 53 months), was available. In
2 of 14 prostate cancers of Gleason grade 1-2 a high HMG-I(Y) 
expression was observed, whereas in 19 of 23 Gleason grade 3, and 34 
of 35 Gleason grade 4-5 tumors, high HMG-I(Y) m RN A  levels were 
detected (chi-square= 38.78, P < 0*0Q01). Moreover, of tumors that 
expressed high HMG-I(Y) levels, 25% were organ confined (Tl-2) in 
contrast to 74.5% of the invading tumors (T3, chi-square =  15.8, p <
0.001). Furthermore, 87% of recurrent tumors showed high HMG-I(Y) 
expression. However, a multivariate regression analysis including Gleason 
grade, tumor stage, HMG-I(Y) expression, and PSA levels showed 
Gleason grade as the most accurate predictor of progression. These 
results, confirm our previous findings in a cohort of radical 
prostatectomy patients. High HMG-I(Y) levels measured by RISH were 
indicative for a worse prognosis, albeit that additional value over the 
more subjective grading methods was not evident.
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PREDICTING PROSTATE CANCER STAGE UTILIZING 
ANGIOGENESJS, GLEASON SCORE AND PSA
Howard Mahran, Bard Diagnostic Sciences, Redmond, WA USA 
David Bostwick, Mayo Clinic Foundation, Rochester, MN USA 
Brian Miles, Baylor University College of Medicine, Houston, TX USA 
Dr. Alan Bennett, C, R. Bard, Inc., Murray Hill, NJ USA
A preoperative method of predicting tumor stage has been shown. The 
method incorporates digital imaging and analysis to characterize an area 
of carcinogenic prostate tissue taken from a needle biopsy. A 
retrospective, blinded, multislte study involving 500 cases was 
conducted. Radical Prostatectomy samples at 3-5mm sections, were 
independently reviewed by blinded referee pathologists to verify 
pathologic stage. Five (5) staging classes were defined: 1) Tumor Organ 
Confined, 2) Capsular Involvement, 3) Extra Capsular Extension, 4) 
Lymphnode métastases and, 5) Bone métastases. Seminal Vesicle 
involvement was also recorded for each stage. One H & E and two 
unstained slides from each positive needle core were supplied for image 
analysis. Each 5 um thick sample was formalin fixed and paraffin 
embedded and then stained for Factor VIII related antigen. At least 3 
fields of cancer were required Tor analysis. Microvessels were counted at 
400x magnification by two independent technicians. Microvessel density 
(MVD) was calculated as the number of microvessels per square 
millimeter of tissue. 100,000 fields were measured. MVD was shown to 
be an independent predictor of tumor stage. A statistical model 
combining MVD, Gleason Score and pre-operative PSA was used to 
produce a quantitative result that was strongly predictive of tumor stage. 
The result significantly enhanced the accuracy of tumor stage prediction 
over Gleason Score and PSA alone.
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PRENATAL ENDOSCOPIC INTRAUTERINE THERAPY; A MONKEY 
MODEL
Wouter F. Feitz, Bas van der Wildt, Eric A. Steegers, Joseph D. de 
Vries.
Dept, of Urology and Obstetrics, Gynaecology, Nijmegen, The 
Netherlands
Prenatal endoscopy was performed in a model for experimental 
surgery in primates. In the rhesus monkey midtrimester endoscopic 
intrauterine access with 3 canula could be successfully achieved in 8 
rhesus monkeys (macaca mulatta). Timing was controlled by physical 
examination and ultrasonographic biometry by which intrauterine 
growth curves could be obtained. Using a seldinger technique and a
1.2 mm introduction sheet with fibertopic endoscope, intrauterine 
inspection could be performed and a second and third operative 4,5
mm port could be introduced under optical control. Fetal conditions 
were monitored by ultrasonography, doppler investigations of the 
umbilical cord and arterial uterina bloodfiow measurements. After 
partial amniotic fluid exchange, adequate fetoscopy was always 
possible. Two monkeys aborted in the 2nd and 6th postoperative day 
respectively. Measurements of electrical uterine activity 24 hours 
postoperatively in the first 5 animals showed no uterine contractions. 
Postoperative prophylactic tocolysis has been abandoned since then. 
Serial ultrasonic investigations for fetal biometry showed no 
disturbance of the intrauterine growth patterns. We currently conclude 
that the rhesus monkey model for experimental intrauterine 
endoscopic surgery seems to be a suitable model in which 
developmental abnormalities of the genitourinary tract can be studied.
